AstraZeneca Enters Exclusive Licensing Agreement for Novel Hyaluronidase ALT-B4 to Advance Subcutaneous Oncology Therapies

Mar 17, 2025 17:31 CST Updated 17:31

Alteogen

Generic Drug Developer

AstraZeneca

Biopharmaceutical Manufacturer

On March 17 local time, AstraZeneca announced that it had reached an agreement with Alteogen Inc.Exclusive License Agreement for ALT-B4 ReachedAccording to the terms of the agreement, AstraZeneca will obtain global rights to use ALT-B4.To develop and commercialize subcutaneous formulations of various oncology assetsAlteogen will be responsible for the clinical and commercial supply of ALT-B4 to AstraZeneca.

Screenshot source: Corporate official website

AstraZeneca will pay Alteogen an upfront payment and additional payments upon achieving specific development, regulatory, and sales-related milestones. In addition, Alteogen will also receive royalties on the sales of commercialized products.

Subcutaneous formulations have many potential advantages, including time savings for patients, clinical staff, and health systems due to shorter administration times.

ALT-B4 is a novel hyaluronidase developed by Alteogen using its Hybrozyme™ platform technology. ALT-B4 enables the administration of drugs typically delivered via intravenous infusion.Large Subcutaneous InjectionALT-B4 achieves this by temporarily hydrolyzing hyaluronic acid in the extracellular matrix.

It is worth mentioning that, previously in 2024On November 9, Daiichi Sankyo also signed an agreement with Alteogen Inc. worth up to$300 million's agreement to jointly develop the subcutaneous formulation of Enhertu, its star HER2 ADC drug co-developed with AstraZeneca.（sc）Injectable formulation.

According to the agreement, Alteogen will receive$20 millionThe upfront payment, and is eligible to receive up to$280 millionMilestone payment.

Cover Source:Company Logo

Disclaimer:This article is for information sharing only,不代表 Insight 立场和观点，也不作治疗方案推荐和介绍。如有需求，请咨询和联系正规医疗机构。

Editor：ccai

PR Article Coordination: WeChat insightxb

SubmissionWeChat: insightxb; Email: insight@dxy.cn

Diversified functions, traceable data……

Insight Database Web Version Awaits Your Experience

Click to read the original text,ImmediatelyUnlock！